Abstract
The calcium binding protein S100B has attracted great attention as a biomarker for a variety of diseases. S100B is mainly expressed in glial cells and functions through intracellular and extracellular signaling pathways. The biological roles of S100B have been closely associated with its concentrations and its physiological states. The released S100B can bind to the receptor of advanced glycation end products and induce the initiation of multiple cell signaling transductions. The regulation of S100B bioactivities has been suggested through phosphoinositide 3 kinase/Akt, p53, mitogen-activated protein kinases, transcriptional factors including nuclear factor-kappaB, and cyclic adenosine monophosphate. The levels of S100B in the blood may function to predict the progress or the prognosis of many kinds of diseases, such as cerebrovascular diseases, neurodegenerative diseases, motor neuron diseases, traumatic brain injury, schizophrenia, depression, diabetes mellitus, myocardial infarction, cancer, and infectious diseases. Given that the activity of S100B has been implicated in the pathological process of these diseases, S100B should not be simply regarded as a biomarker, it may also function as therapeutic target for these diseases. Further elucidation of the roles of S100B may formulate innovative therapeutic strategies for multiple diseases.
Keywords: RAGE, PI3K, MAPK, neurodegeneration, stroke, diabetes, biomarker.
Current Medicinal Chemistry
Title:Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Volume: 23 Issue: 15
Author(s): Zhao Zhong Chong, Benjarat Changyaleket, Haoliang Xu, Randy O. Dull and David E. Schwartz
Affiliation:
Keywords: RAGE, PI3K, MAPK, neurodegeneration, stroke, diabetes, biomarker.
Abstract: The calcium binding protein S100B has attracted great attention as a biomarker for a variety of diseases. S100B is mainly expressed in glial cells and functions through intracellular and extracellular signaling pathways. The biological roles of S100B have been closely associated with its concentrations and its physiological states. The released S100B can bind to the receptor of advanced glycation end products and induce the initiation of multiple cell signaling transductions. The regulation of S100B bioactivities has been suggested through phosphoinositide 3 kinase/Akt, p53, mitogen-activated protein kinases, transcriptional factors including nuclear factor-kappaB, and cyclic adenosine monophosphate. The levels of S100B in the blood may function to predict the progress or the prognosis of many kinds of diseases, such as cerebrovascular diseases, neurodegenerative diseases, motor neuron diseases, traumatic brain injury, schizophrenia, depression, diabetes mellitus, myocardial infarction, cancer, and infectious diseases. Given that the activity of S100B has been implicated in the pathological process of these diseases, S100B should not be simply regarded as a biomarker, it may also function as therapeutic target for these diseases. Further elucidation of the roles of S100B may formulate innovative therapeutic strategies for multiple diseases.
Export Options
About this article
Cite this article as:
Chong Zhong Zhao, Changyaleket Benjarat, Xu Haoliang, Dull O. Randy and Schwartz E. David, Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases, Current Medicinal Chemistry 2016; 23 (15) . https://dx.doi.org/10.2174/0929867323666160406121117
DOI https://dx.doi.org/10.2174/0929867323666160406121117 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells
Anti-Cancer Agents in Medicinal Chemistry Calcium Ion – The Key Player in Cerebral Ischemia
Current Medicinal Chemistry Cardiopulmonary Interactions in Children with Heart Failure
Current Cardiology Reviews “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Effect of Trichostatin A on Gelsolin Levels, Proteolysis of Amyloid Precursor Protein, and Amyloid Beta-Protein Load in the Brain of Transgenic Mouse Model of Alzheimer's Disease
Current Alzheimer Research Harvesting New Therapeutic Avenues with Stem Cell Applications
Current Neurovascular Research Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry Kinins and Cardiovascular Diseases
Current Pharmaceutical Design NMR in Metabolic Profiles of Neural Stem/Progenitor Cells: Current Status and Relevant Problems
Current Medical Imaging Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine The Role of Negative Costimulators During Parasitic Infections
Endocrine, Metabolic & Immune Disorders - Drug Targets Anthrax Fusion Protein Therapy of Cancer
Current Protein & Peptide Science Mitochondria: A Target for Neuroprotective Interventions in Cerebral Ischemia-Reperfusion
Current Pharmaceutical Design Normobaric Hyperoxia Preconditioning Induces Changes in the Brain Lipidome
Current Neurovascular Research Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) RNase Therapy Assessed by Magnetic Resonance Imaging Reduces Cerebral Edema and Infarction Size in Acute Stroke
Current Neurovascular Research The Role of Neuropeptides and Neurohormones in Neurogenic Cardiac Arrhythmias
Current Drug Targets - Cardiovascular & Hematological Disorders